<DOC>
	<DOC>NCT02973269</DOC>
	<brief_summary>The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.</brief_summary>
	<brief_title>DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis</brief_title>
	<detailed_description />
	<mesh_term>Fasciitis</mesh_term>
	<mesh_term>Fasciitis, Plantar</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Written informed consent, including authorization to release health information Skeletally mature, male or female patients 18 to 65 years of age with diagnosis of plantar fasciitis Persistent heel pain for more than three months Women of child bearing potential must have a negative urine pregnancy test (UPT) at Screening Visit and must use an effective method of birth control during the course of the study Previous surgery on the midfoot or hindfoot Neuromuscular disease Systemic muscle weakness Planning a pregnancy during the study Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to first visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>